A new guideline, the 2024 Updated ACR Guideline for the Diagnosis and Treatment of Lupus Nephritis, is being introduced at ACR Convergence 2024 on Monday, Nov. 18. In the session, Lisa Sammaritano, MD, professor of clinical medicine at Weill Cornell Medicine and Hospital for Special Surgery, New York, will discuss the guideline development process and…
Hosted by Jonathan S. Hausmann, MD, a pediatric and adult rheumatologist at Boston Children’s Hospital and Beth Israel Deaconess Medical Center, and an instructor in medicine at Harvard Medical School, ACR on Air debuted in 2019. In this episode, ACR Master (2016) Philip J. Mease, MD, joins Dr. Hausmann for a deep dive into psoriatic…
Celebrating its long history, the Division of Rheumatology & Immunology at Medical University of South Carolina has made strides in scleroderma, lupus and more.
An engaging mix of new and returning programming is planned for ACR Convergence in Washington, D.C. “ACR Convergence is unique because of the blend of high-quality science, updates on advances in clinical care and networking opportunities to advance the field of rheumatology,” says Annual Meeting Planning Committee (AMPC) Chair Gregory C. Gardner, MD, MACP. “We…
Upadacitinib, as a tablet and oral solution, is now FDA approved to treat children age 2 years and older with active polyarticular juvenile idiopathic arthritis or psoriatic arthritis.
Dr. Megan Cooper Appointed Director of Pediatric Rheumatology & Immunology Division at WashU Megan A. Cooper, MD, PhD, a physician-scientist recognized internationally for her work in pediatric immunodeficiencies and immune dysregulation, took the reins of the Division of Pediatric Rheumatology and Immunology at Washington University School of Medicine, St. Louis, as director this past fall….
For a podcast audience, Dr. Sunil Abraham shared pearls for evaluating what setting best fits you and your lifestyle, and what a career in community practice means.
Although research is still emerging, evidence suggests changes in climate, such as increases in heat, pollution and allergens, may increase the risk of flare and hospitalization in patients with rheumatoid arthritis, systemic lupus erythematosus and other rheumatic conditions. Paul Dellaripa, MD, discussed the research and how rheumatologists can help their patients.
The FDA has granted sarilumab its first pediatric indication, approving the agent to treat active, polyarticular juvenile idiopathic arthritis (pJIA) in patients who weigh at least 63 kgs.